Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis. 

Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. 

Observed incidence rates of uveitis following certolizumab pegol treatment in patients with axial spondyloarthritis. 

Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. 

Reinduction with certolizumab pegol in patients with Crohn’s disease experiencing disease exacerbation: 7-year data from the PRECiSE 4 study. 

Safety of long-term treatment with certolizumab pegol in patients with Crohn’s disease, based on a pooled analysis of data from clinical trials. 

Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial. 

Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials. 

Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population. 

Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis. 

Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumor necrosis factor exposure.